Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient’s body and may […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!